Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs)

Receptor-interacting serine/threonine protein kinase 2 (RIPK2) has been demonstrated to be a promising target for treating inflammatory diseases. Herein, we describe the discovery and optimization of a series of RIPK2 inhibitors derived from an FLT3 inhibitor, CHMFL-FLT3-165. Compound 10w was identi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2022-07, Vol.65 (13), p.9312-9327
Hauptverfasser:	Yuan, Xue, Chen, Yong, Tang, Minghai, Wei, Yuhan, Shi, Mingsong, Yang, Yingxue, Zhou, Yanting, Yang, Tao, Liu, Jiang, Liu, Kongjun, Deng, Dexin, Zhang, Chufeng, Chen, Lijuan
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!